ARCT
Arcturus Therapeutics Holdings Inc.
Next earnings Aug 10, 2026 · consensus $-1.05 EPS, $3.48M rev
Last earnings -2.5% on 2026-05-07
$6.88
▲ +0.88%$6.88▼ -45.00%
over 1Y
L $5.90EODHDH $23.16
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.9%
1W-4.8%
1M-10.2%
3M+1.8%
YTD+10.1%
1Y-45.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 18 analysts
Buy
Conservative balance sheet (liabilities/equity 0.27x); but revenue fell -46.1% YoY.
Revenue (FY2025) $82.0M · FY2025
Arcturus Therapeutics Holdings Inc. shows $82.0M in FY2025 revenue (-46.1% YoY), a -80.2% net margin, and -30.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $12.4M | $206M | $167M | $152M | $82.0M |
| Gross profit | — | — | — | — | — |
| Operating income | -$203M | $12.2M | -$78.2M | -$95.7M | -$76.3M |
| Net income | -$204M | $9.35M | -$29.7M | -$80.9M | -$65.8M |
| Diluted EPS | -$7.74 | $0.35 | -$1.12 | -$3.00 | -$2.40 |
| Net margin | -1648.0% | 4.5% | -17.8% | -53.1% | -80.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$65.9M
EV / EBITDA—
EV / Sales0.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-33.6%
FCF yield-38.1%
Quality & risk
ROIC (est.)-19.1%
Free cash flow-$74.5M
Total debt$101M
Net cash$130M
Altman Z-Score-0.32 distress
Piotroski F-Score1/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+4.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Shareholder vote2026-06-05
- 8-K Officer / director change2026-05-07
- 10-Q Quarterly report2026-05-07
- DEF 14A Proxy statement2026-04-24
- 8-K Earnings results2026-03-03
- 10-K Annual report2026-03-03
- S-3 Shelf registration (potential raise)2025-12-30
- 8-K Officer / director change2025-12-15
- 10-Q Quarterly report2025-11-12
Recent filings
all on EDGAR ↗4Period ending 2026-06-052026-06-15open ↗4Period ending 2026-06-052026-06-15open ↗4Period ending 2026-06-052026-06-15open ↗4Period ending 2026-06-052026-06-15open ↗4Period ending 2026-06-052026-06-15open ↗4Period ending 2026-06-052026-06-15open ↗4Period ending 2026-06-052026-06-15open ↗8-KPeriod ending 2026-06-052026-06-05open ↗4Period ending 2026-05-012026-05-07open ↗3Period ending 2026-05-012026-05-07open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-012026-05-07open ↗
Frequently asked
- Is Arcturus Therapeutics Holdings Inc. (ARCT) a buy?
- ARCT currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.27x); but revenue fell -46.1% YoY.
- What is Arcturus Therapeutics Holdings Inc.'s quality score?
- ARCT scores 50.058823529411754/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001768224, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:57:27 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.